Ryan W. Huey, MD, MS

Peer-Reviewed Articles

1. Huey RW, Shah AT, Reddi HV, Dasari P, Topham JT, Hwang H, Dhillon N, Willett A, Smaglo BG, Estrella JS, Rashid A, Matamoros A, Overman MJ, Choquette L, Omerza G, Kelly K, Wang X, Loree JM, Rueter J, Varadhachary GR, Raghav K. Feasibility and value of genomic profiling in cancer of unknown primary: real-world evidence from prospective profiling study. J Natl Cancer Inst 115(8):994-997, 2023. PMID: 37202363.
2. Morris VK, Jazaeri A, Westin SN, Pettaway C, George S, Huey RW, Grinsfelder M, Shafer A, Johnson B, Vining D, Guo M, Fellman B, Frumovitz M. Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent/Metastatic Human Papillomavirus-Associated Cancers. Oncologist 28(7):618-623, 2023. PMID: 37104874.
3. Rogers JE, Sirisaengtaksin A, Leung M, Morris VK, Xiao L, Huey R, Wolff R, Eng C, Vauthey JN, Tzeng CD, Johnson B. Hepatic Metastasectomy in Squamous Cell Carcinoma of the Anal Canal: A Case Series of a Curative Approach. Cancers (Basel) 15(15), 2023. e-Pub 2023. PMID: 37568706.
4. Zeineddine FA, Zeineddine MA, Yousef A, Gu Y, Chowdhury S, Dasari A, Huey RW, Johnson B, Kee B, Lee MS, Morelli MP, Morris VK, Overman MJ, Parseghian C, Raghav K, Willis J, Wolff RA, Kawaguchi Y, Vauthey JN, Sun R, Kopetz S, Shen JP. Survival improvement for patients with metastatic colorectal cancer over twenty years. NPJ Precis Oncol 7(1):16, 2023. e-Pub 2023. PMID: 36781990.
5. Serpas Higbie V, Rogers J, Hwang H, Qiao W, Xiao L, Dasari A, Mola-Rudd K, Morris VK, Wolff RA, Raghav K, Huey R, Parseghian C, Willis J, Kopetz S, Overman MJ, Johnson B. Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience. Oncologist 27(11):952-957, 2022. PMID: 35946836.
6. Morris VK, Overman MJ, Lam M, Parseghian CM, Johnson B, Dasari A, Raghav K, Kee BK, Huey R, Wolff RA, Shen JP, Li J, Zorrilla I, Tzeng CD, Tran Cao HS, Chun YS, Newhook TE, Vauthey N, Duose D, Luthra R, Haymaker C, Kopetz S. Bintrafusp alfa, an anti-PD-L1:TGF-β trap fusion protein, in patients with ctDNA-positive, liver-limited metastatic colorectal cancer. Cancer Res Commun 2(9):979-986, 2022. e-Pub 2022. PMID: 36382087.
7. Christine Megerdichian Parseghian, Eduardo Vilar Sanchez, Ryan Sun, Madhulika Eluri, Van K Morris, Benny Johnson, Maria Pia Morelli, Michael J Overman, Jason Willis, Ryan Huey, Kanwal Pratap Singh Raghav, Arvind Dasari, Bryan K Kee, Robert A Wolff, John Paul YC Shen, Scott Kopetz. Phase 2 study of anti-EGFR rechallenge therapy with panitumumab with or without trametinib in advanced colorectal cancer. Journal of Clinical Oncology 40(16_suppl):3520-3520, 2022.
8. Benny Johnson, Dong Yang, Hiba I Dada, Van K Morris, Xuemei Wang, Arvind Dasari, Kanwal Pratap Singh Raghav, Bryan K Kee, John Paul YC Shen, Ryan Huey, Michael Sangmin Lee, Christine Megerdichian Parseghian, Phat Le, Maria Pia Morelli, Jason Willis, Robert A Wolff, Leylah Drusbosky, Michael J Overman, Scott Kopetz. RAS co-mutation and early onset disease represent an aggressive phenotype of atypical (non-V600) BRAF mutant metastatic colorectal cancer. Journal of Clinical Oncology 40(16_suppl):3592-3592, 2022.
9. Raghav K, Hwang H, Jácome AA, Bhang E, Willett A, Huey RW, Dhillon NP, Modha J, Smaglo B, Matamoros A, Estrella JS, Jao J, Overman MJ, Wang X, Greco FA, Loree JM, Varadhachary GR. Development and Validation of a Novel Nomogram for Individualized Prediction of Survival in Cancer of Unknown Primary. Clin Cancer Res 27(12):3414-3421, 2021. e-Pub 2021. PMID: 33858857.
10. Allen CJ, Eska JS, Thaker NG, Feeley TW, Kaplan RS, Huey RW, Tzeng CD, Lee JE, Frank SJ, Aloia TA, Gottumukkala V, Katz MHG. Developing a Value Framework: Utilizing Administrative Data to Assess an Enhanced Care Initiative. J Surg Res 262:115-120, 2021. e-Pub 2021. PMID: 33561722.
11. Huey RW, Smaglo BG, Estrella JS, Matamoros A, Overman MJ, Varadhachary GR, Raghav KPS. Cancer of Unknown Primary Presenting as Bone-Predominant or Lymph Node-Only Disease: A Clinicopathologic Portrait. Oncologist 26(4):e650-e657, 2021. e-Pub 2021. PMID: 33524217.
12. Huey RW, George GC, Phillips P, White R, Fu S, Janku F, Karp DD, Naing A, Piha-Paul S, Subbiah V, Tsimberidou AM, Pant S, Yap TA, Rodon J, Meric-Bernstam F, Shih YT, Hong DS. Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials. Oncologist. e-Pub 2021. PMID: 33783054.
13. Augustyn A, Reed VI, Ahmad N, Bhutani MS, Bloom ES, Bowers JR, Chronowski GM, Das P, Holliday EB, Delclos ME, Huey RW, Koay EJ, Lee SS, Nelson CL, Taniguchi CM, Koong AC, Chun SG. Implementation of a stereotactic body radiotherapy program for unresectable pancreatic cancer in an integrated community academic radiation oncology satellite network. Clin Transl Radiat Oncol 27:147-151, 2021. e-Pub 2021. PMID: 33665384.
14. Allen CJ, Thaker NG, Prakash L, Kruse BC, Feeley TW, Kaplan RS, Huey R, Frank SJ, Aloia TA, Gottumukkala V, Katz MHG. Communicating Value: Use of a Novel Framework in the Assessment of an Enhanced Recovery Initiative. Ann Surg 273(1):e7-e9, 2021. e-Pub 2020. PMID: 32568750.
15. Huey RW, Makawita S, Xiao L, Matamoros A, Estrella JS, Overman MJ, Varadhachary GR, Raghav K. Sarcomatoid carcinoma presenting as cancers of unknown primary: a clinicopathological portrait. BMC Cancer 19(1):965, 2019. e-Pub 2019. PMID: 31623602.
16. Selig BP, Furr JR, Huey RW, Moran C, Alluri VN, Medders GR, Mumm CD, Hallford HG, Mulvihill JJ. Cancer chemotherapeutic agents as human teratogens. Birth Defects Res A Clin Mol Teratol 94(8):626-50, 2012. e-Pub 2012. PMID: 22851372.
17. Teague TK, Tan C, Marino JH, Davis BK, Taylor AA, Huey RW, Van De Wiele CJ. CD28 expression redefines thymocyte development during the pre-T to DP transition. Int Immunol 22(5):387-97, 2010. e-Pub 2010. PMID: 20203098.

Editorials

1. Lyu HG, Gordon WJ, Huey RW, Katz MHG. Leveraging the 21st Century Cures Act to Improve Cancer Care, Patient Engagement, and Data Collection. JCO Oncol Pract 18(12):788-790, 2022. PMID: 36219810.
2. Huey RW, Hawk E, Offodile AC. Mind the Gap: Precision Oncology and Its Potential to Widen Disparities. J Oncol Pract 15(6):301-304, 2019. PMID: 31112478.

Abstracts

1. Kanwal P Raghav, Bettzy Stephen, Daniel D Karp, Sarina A Piha-Paul, David S Hong, Dipti Jain, Dilichukwu O Chudy Onwugaje, Abdulrahman Abonofal, Anneleis F Willett, Michael Overman, Brandon Smaglo, Ryan W Huey, Funda Meric-Bernstam, Gauri R Varadhachary, Aung Naing. Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial. Journal for immunotherapy of cancer 10(5), 2022. PMID: 35618285.
2. Raghav KP, Stephen B, Karp DD, Piha-Paul SA, Hong DS, Jain D, Chudy Onwugaje DO, Abonofal A, Willett AF, Overman M, Smaglo B, Huey RW, Meric-Bernstam F, Varadhachary GR, Naing A. Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial. J Immunother Cancer 10(5), 2022. PMID: 35618285.
3. Stephen Chun, Alexander Augustyn, Valerie Reed, Neelofur Ahmad, Manoop Bhutani, Elizabeth S Bloom, John Bowers, Gregory Chronowski, Prajnan Das, Emma Holliday, Marc Delclos, Ryan Huey, Eugene J Koay, Sunyoung Lee, Christopher Nelson, Cullen Taniguchi, Albert Koong. Implementation of a Stereotactic Body Radiotherapy Program for Unresectable Pancreatic Cancer in an Integrated Community Academic Radiation Oncology Satellite Network. Cureus Journal of Medical Science 14(2), 2022.
4. Van K. Morris, Christine Megerdichian Parseghian, Michelle Escano, Benny Johnson, Kanwal Pratap Singh Raghav, Arvind Dasari, Ryan Huey, Michael J. Overman, Jason Willis, Michael Sangmin Lee, Robert A. Wolff, Bryan K. Kee, John Paul Y.C. Shen, Maria Pia Morelli, Alda Tam, Wai Chin Foo, Lianchun Xiao, Scott Kopetz. Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAFV600E metastatic colorectal cancer 40(4_suppl):12-12, 2022.